The collaboration will build upon foundational "field of injury" science -- where genomic changes associated with lung cancer can be identified with a simple brushing of a person's airway -- to develop new interventions that can save lives.
Under terms of the agreement, Veracyte and the Lung Cancer Initiative at Johnson and Johnson, whose mission is to prevent, intercept and cure lung cancer, will combine clinical study cohorts involving more than 5,000 patients with multiple years of clinical outcome data.
Veracyte will contribute bronchial and nasal samples from its clinical trials, which are part of the company's extensive lung cancer-focused biorepository.
Veracyte will deploy its RNA whole-transcriptome sequencing platform, utilising high-dimensional data and machine learning pipelines on the combined cohort, providing the most comprehensive genomic content available which the Lung Cancer Initiative at Johnson and Johnson will have access to for therapeutic purposes.
The collaboration is expected to accelerate two key lung cancer programs for Veracyte.
First, the development of the first non-invasive nasal swab test for early lung cancer detection and, secondly, the commercialisation of its Percepta classifier on the company's RNA whole-transcriptome sequencing platform, which, as a result of this collaboration, is expected to launch in the first half of 2019.
Veracyte (NASDAQ: VCYT) is a genomic diagnostics company that improves patient care by providing trustworthy and actionable answers to challenging clinical questions.
The company's products uniquely combine advanced genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward, informing both diagnosis and treatment decisions without the need for costly, risky surgeries that are often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. Veracyte is based in South San Francisco, California.
Merck reports positive Phase 3 results for WINREVAIR in pulmonary arterial hypertension
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
Sanofi expedites Beyfortus shipments to support early RSV season readiness
Mediar Therapeutics reports first IPF patient dosed in MTX-463 Phase 2 trial
Innovent's IBI363 granted second breakthrough therapy designation in China
bioMérieux launches rapid PCR test for equine respiratory diseases
BioNTech and Bristol Myers Squibb partner to co-develop bispecific antibody for solid tumours
Taiho Oncology and Cullinan Therapeutics report REZILIENT1 Phase 1/2 data
BioCryst showcases consistent efficacy of ORLADEYO across all age groups in HAE treatment